


## AMENDMENTS TO THE CLAIMS

1. (Withdrawn) A method of protecting a patient from one or more treatments that trigger apoptosis comprising administering to the patient a composition comprising a pharmaceutically acceptable amount of a PTEN inhibitor selected from the group consisting of compounds I-XIV.
2. (Withdrawn) The method of claims 1, wherein the treatment is a cancer treatment.
3. (Withdrawn) The method of claim 2, wherein the PTEN inhibitor is administered prior to, together with, or after a treatment for the cancer.
4. (Withdrawn) The method of claim 2, wherein the treatment is chemotherapy or radiation therapy.
5. (Previously Presented) A method of treating a patient suffering from damage to normal tissue attributable to stressheart disease, comprising administering to the patient a composition comprising a pharmaceutically acceptable amount of a PTEN inhibitor ~~selected from the group consisting of compounds I-XIV~~ having the formula:



wherein,

R<sup>1</sup> represents H, NO<sub>2</sub>, NR<sup>5</sup>R<sup>6</sup>, halogen, cyano, alkyl, alkylaryl, carbonyl, carboxy, COR<sup>2</sup>, or CONR<sup>5</sup>R<sup>6</sup>;

R<sup>2</sup> and R<sup>3</sup> independently represent H, C<sup>1</sup>-C<sup>4</sup> alkyl, aryl, or alkylaryl;

R<sup>4</sup> represents H, C<sup>1</sup>-C<sup>4</sup>, alkyl, aryl, alkylaryl, SO<sub>2</sub>R<sup>2</sup>, NHSO<sub>2</sub>R<sup>2</sup>, NHCO<sup>2</sup>R<sup>2</sup>, NHCO<sub>2</sub>R<sup>2</sup>, N=CR<sup>2</sup>R<sup>3</sup>, or NR<sup>5</sup>R<sup>6</sup>;

R<sup>5</sup> and R<sup>6</sup> independently represent H, C<sup>1</sup>-C<sup>4</sup> alkyl, aryl, alkylaryl, (CH<sub>2</sub>)<sub>n</sub>COXR<sup>2</sup>, (CH<sub>2</sub>)<sub>n</sub>XR<sup>2</sup>, (CH<sub>2</sub>)<sub>n</sub>CO(CH<sub>2</sub>)<sub>m</sub>XR<sup>2</sup>, SO<sub>2</sub>R<sup>2</sup>, (CH<sub>2</sub>)<sub>n</sub>CO(CH<sub>2</sub>)<sub>m</sub>COXR<sup>2</sup>, or (CH<sub>2</sub>)<sub>n</sub>XR<sup>2</sup>;

m=0-3;

n=0-3; and

X represents CR<sup>2</sup>R<sup>3</sup>, O, or NR<sup>4</sup>.

6. (Previously Presented) The method of claim 5, wherein the PTEN inhibitor is administered prior to, together with, or after a treatment for a disease suffered by the patient.

7. (Withdrawn) A method of sensitizing cancer cells to an inhibitor of the PI3 kinase pathway comprising administering to a patient in need of such treatment a PTEN inhibitor selected from the group consisting of compounds I-XIV.

8. (Withdrawn) A method of treating apoptosis associated with a medical procedure comprising administering to a patient in need of such treatment a PTEN inhibitor selected from the group consisting of compounds I-XIV.

9. (Withdrawn) A method of protecting a patient from radiation or chemical exposure comprising administering to the patient a composition comprising a pharmaceutically acceptable amount of a PTEN inhibitor selected from the group consisting of compounds I-XIV.

10. (Withdrawn) The method of claim 9 wherein the PTEN inhibitor is administered prior to, together with, or after the said radiation or chemical exposure.

11. (Withdrawn) A method of sensitizing cancer stem cells by exposing said cells to a PTEN inhibitor selected from the group consisting of compounds I-XIV.

12. (Withdrawn) The method of claim 9 wherein the PTEN inhibitor is administered prior to, together with, or after a treatment for a disease suffered by the patient.